Multicenter Studies of Lamivudine for the Treatment and Prevention of Hepatitis B After Liver Transplantation

References

1. 1.
   1. O'Grady JG,
   2. Smith HM,
   3. Davies SE

   (1992) Hepatitis B virus reinfection after orthotopic liver transplantation. J Hepatol 14:104–111, pmid:1737910. et al.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.
   1. Todo S,
   2. DeMetris AJ,
   3. Van Thiel D

   (1991) Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13:619–626, pmid:2010156. et al.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.
   1. Terasaki-Cecha

   1. Belle HS,
   2. Beringer KC,
   3. Detre KM

   (1995) in Clinical Transplants. An update on liver transplantation in the US: recipient characteristics and outcome, ed Terasaki-Cecha (UCLA Tissue Typing Laboratory, Los Angeles), pp 1–15.
4. 4.
   (1991) Medicare program: criteria for Medicare coverage of adult liver transplants-HCFA (Final notice. Fed. Regist), 56, pp 15006–15018.
5. 5.
   1. Mela J,
   2. Wooten RS,
   3. Batts KP

   (1989) Failure of interferon to prevent recurrent hepatitis B infection in hepatic allograft. Mayo Clin Proc 64:429–432, pmid:2654499. et al.

   OpenUrlPubMed
6. 6.
   1. Terrault NA,
   2. Holland CC,
   3. Ferrell L

   (1996) Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transplant Surg 2:132–138. et al.

   OpenUrl
7. 7.
   1. Tyrrell DLJ,
   2. Fischer K,
   3. Sayani K

   (1993) Treatment of chimpanzees and ducks with lamivudine, 2'3‘-dideoxy-3’-thiacytidine results in a rapid suppression of hepadnaviral DNA in sera. Clini Invest Med 16:B77. et al.

   OpenUrl
8. 8.
   1. Dienstag JL,
   2. Perrillo RP,
   3. Schiff ER

   (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657–1661, pmid:7477217. et al.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.
   1. Perrillo R,
   2. Rakela J,
   3. Martin P

   (1997) Long term lamivudine therapy of patients with recurrent hepatitis B post liver transplantation. Hepatology 26:177A. et al.

   OpenUrl
10. 10.
    1. Knodell RG,
    2. Ishak KG,
    3. Black WC

    (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1, 431435. et al.
11. 11.
    1. Bartholomew MM,
    2. Jansen RW,
    3. Jeffers LJ

    (1997) Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20–22, pmid:8988118. et al.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.
    1. Melegari M,
    2. Scaglioni PP,
    3. Wands JR

    (1998) Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628–633, pmid:9462667.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.
    1. Samuel D,
    2. Muller R,
    3. Alexander G

    (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329:1842–1847, pmid:8247035. et al.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.
    1. Terrault NA,
    2. Zhou S,
    3. McCory RW

    (1998) Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 28:555–561, pmid:9696024. et al.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.
    1. Perrillo R,
    2. Rakela J,
    3. Martin P

    (1997) Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT). Hepatology 26:260A. et al.

    OpenUrlCrossRef